David A. Ramsay Buys 37,124 Shares of Savara Inc (NASDAQ:SVRA) Stock

Posted by on May 28th, 2023

Savara Inc (NASDAQ:SVRA – Get Rating) Director David A. Ramsay acquired 37,124 shares of Savara stock in a transaction on Friday, May 26th. The shares were purchased at an average price of $2.63 per share, for a total transaction of $97,636.12. Following the completion of the acquisition, the director now directly owns 2,201,142 shares in the company, valued at $5,789,003.46. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Savara Price Performance

Shares of SVRA opened at $2.66 on Friday. Savara Inc has a fifty-two week low of $1.08 and a fifty-two week high of $2.85. The company has a debt-to-equity ratio of 0.27, a quick ratio of 23.90 and a current ratio of 23.90. The business’s 50-day moving average is $1.99 and its two-hundred day moving average is $1.97. The company has a market capitalization of $303.43 million, a P/E ratio of -9.85 and a beta of 0.86.

Savara (NASDAQ:SVRA – Get Rating) last issued its quarterly earnings data on Thursday, March 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Research analysts predict that Savara Inc will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Jane Street Group LLC lifted its stake in shares of Savara by 22.0% in the 4th quarter. Jane Street Group LLC now owns 20,757 shares of the company’s stock valued at $32,000 after purchasing an additional 3,746 shares during the last quarter. Renaissance Technologies LLC lifted its position in Savara by 25.0% in the third quarter. Renaissance Technologies LLC now owns 70,000 shares of the company’s stock valued at $109,000 after buying an additional 14,000 shares during the last quarter. AXA S.A. boosted its stake in Savara by 0.4% during the third quarter. AXA S.A. now owns 3,426,215 shares of the company’s stock worth $5,311,000 after buying an additional 14,736 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Savara during the first quarter valued at about $32,000. Finally, Millennium Management LLC raised its stake in shares of Savara by 12.3% in the 2nd quarter. Millennium Management LLC now owns 156,314 shares of the company’s stock valued at $238,000 after acquiring an additional 17,093 shares during the period. Institutional investors and hedge funds own 75.51% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on SVRA. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Savara in a research report on Tuesday, April 4th. Jefferies Financial Group raised shares of Savara from a “hold” rating to a “buy” rating and raised their target price for the company from $2.00 to $4.00 in a research report on Tuesday, May 16th.

Savara Company Profile

(Get Rating)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Read More

Insider Buying and Selling by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.